Grifols (GIKLY) Net Income towards Common Stockholders (2010 - 2019)
Grifols (GIKLY) posted Net Income towards Common Stockholders of $330.1 million for Q1 2020, down 55.46% quarter-over-quarter from $741.2 million in Q4 2019, and up 69.41% year-on-year from $194.8 million in Q2 2019.
Grifols (GIKLY) Net Income towards Common Stockholders (2010 - 2019) Analysis & Trends
Grifols (GIKLY) has reported Net Income towards Common Stockholders for 11 consecutive years, with $330.1 million the latest figure, recorded in Q1 2020.
- Net Income towards Common Stockholders for Q1 2020 came in at $330.1 million, up 69.41% year-over-year; the trailing twelve-month figure through Dec 2021 was $330.1 million (down 69.19% YoY), and the FY2025 annual result was $467.9 million, up 178.92% from the prior year.
- Net Income towards Common Stockholders was $330.1 million for Q1 2020 at Grifols, down from $741.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $882.3 million in Q4 2017 and troughed at $136.4 million in Q2 2016.
- Average Net Income towards Common Stockholders over 5 years is $358.1 million, with a median of $247.9 million recorded in 2017.
- Year-over-year, Net Income towards Common Stockholders soared 92655.59% in 2016 and plunged 35.0% in 2017.
- Over 5 years, Net Income towards Common Stockholders stood at $150.5 million in 2016, then surged by 486.37% to $882.3 million in 2017, then decreased by 9.06% to $802.4 million in 2018, then slipped by 7.63% to $741.2 million in 2019, then sank by 55.46% to $330.1 million in 2020.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $330.1 million in Q1 2020, $741.2 million in Q4 2019, and $194.8 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.33 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 1.65 |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 741.18 Mn |
| Dec 31, 2018 | 802.38 Mn |
| Dec 31, 2017 | 882.31 Mn |
| Dec 31, 2016 | 150.47 Mn |
| Dec 31, 2015 | 143.08 Mn |
| Sep 30, 2015 | 155.84 Mn |
| Jun 30, 2015 | 147,000.37 |
| Dec 31, 2014 | -423.67 Mn |
| Sep 30, 2014 | 151.51 Mn |
| Jun 30, 2014 | 142,485.34 |
| Mar 31, 2014 | 165.78 Mn |
| Dec 31, 2013 | -363.46 Mn |
| Sep 30, 2013 | 111.62 Mn |
| Jun 30, 2013 | 119.87 Mn |
| Mar 31, 2013 | 120.15 Mn |
| Dec 31, 2012 | -255.93 Mn |
| Sep 30, 2012 | 79.85 Mn |
| Jun 30, 2012 | 84.76 Mn |
| Mar 31, 2012 | 88.55 Mn |
| Dec 31, 2011 | -59.02 Mn |